{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:18:22Z","timestamp":1793665102526,"version":"4.5.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-025-00941-2","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T17:10:57Z","timestamp":1743786657000},"page":"1173-1183","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-9635","authenticated-orcid":false,"given":"Guillaume","family":"Cartron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-8213","authenticated-orcid":false,"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassine","family":"Al Tabaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Le Bras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Ysebaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7791-0470","authenticated-orcid":false,"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6804-7943","authenticated-orcid":false,"given":"Fabrice","family":"Jardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7032-5180","authenticated-orcid":false,"given":"Jacques-Olivier","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-3039","authenticated-orcid":false,"given":"Fran\u00e7ois-Xavier","family":"Gros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gastinne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-2448","authenticated-orcid":false,"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Joris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Ricard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Regny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurianne","family":"Drieu La Rochelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Feugier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6844-7920","authenticated-orcid":false,"given":"Ambroise","family":"Marcais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Griolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6809-917X","authenticated-orcid":false,"given":"Karin","family":"Tarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sesques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"941_CR1","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1182\/blood-2019-127719","volume":"134","author":"AS Halwani","year":"2019","unstructured":"Halwani, A. S. et al. Survival patterns in patients with relapsed or refractory diffuse large B cell lymphoma: treatment trajectories and responses after the first relapse. Blood 134, 1622 (2019).","journal-title":"Blood"},{"key":"941_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","volume":"63","author":"G Kanas","year":"2022","unstructured":"Kanas, G. et al. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020\u20132025. Leuk. Lymphoma 63, 54\u201363 (2022).","journal-title":"Leuk. Lymphoma"},{"key":"941_CR3","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly, H. et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26, v116\u2013v125 (2015).","journal-title":"Ann. Oncol."},{"key":"941_CR4","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","volume":"21","author":"AD Zelenetz","year":"2023","unstructured":"Zelenetz, A. D. et al. NCCN Guidelines\u00ae insights: B-cell lymphomas, version 6.2023. J. Natl Compr. Canc. Netw. 21, 1118\u20131131 (2023).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"941_CR5","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn, L. H. & Salles, G. Diffuse large B-cell lymphoma. N. Engl. J. Med. 384, 842\u2013858 (2021).","journal-title":"N. Engl. J. Med."},{"key":"941_CR6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640\u2013654 (2022).","journal-title":"N. Engl. J. Med."},{"key":"941_CR7","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 141, 1675\u20131684 (2023).","journal-title":"Blood"},{"key":"941_CR8","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","volume":"29","author":"R Houot","year":"2023","unstructured":"Houot, R. et al. Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat. Med. 29, 2593\u20132601 (2023).","journal-title":"Nat. Med."},{"key":"941_CR9","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","volume":"23","author":"A Sehgal","year":"2022","unstructured":"Sehgal, A. et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 23, 1066\u20131077 (2022).","journal-title":"Lancet Oncol."},{"key":"941_CR10","first-page":"1832","volume":"137","author":"JY Spiegel","year":"2021","unstructured":"Spiegel, J. Y. et al. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood 137, 1832\u20131835 (2021).","journal-title":"Blood"},{"key":"941_CR11","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1182\/blood.2022016945","volume":"140","author":"R Di Blasi","year":"2022","unstructured":"Di Blasi, R. et al. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood 140, 2584\u20132593 (2022).","journal-title":"Blood"},{"key":"941_CR12","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","volume":"24","author":"M Bacac","year":"2018","unstructured":"Bacac, M. et al. CD20\u2013TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin. Cancer Res. 24, 4785\u20134797 (2018).","journal-title":"Clin. Cancer Res."},{"key":"941_CR13","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson, M. J. et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 387, 2220\u20132231 (2022).","journal-title":"N. Engl. J. Med."},{"key":"941_CR14","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/JCO.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings, M. et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J. Clin. Oncol. 39, 1959\u20131970 (2021).","journal-title":"J. Clin. Oncol."},{"key":"941_CR15","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878\u20131887 (2020).","journal-title":"Nat. Med."},{"key":"941_CR16","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 4898\u20134911 (2020).","journal-title":"Blood Adv."},{"key":"941_CR17","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.3390\/cancers13174279","volume":"13","author":"S Lamure","year":"2021","unstructured":"Lamure, S. et al. Clinical and product features associated with outcome of DLBCL patients to CD19-targeted CAR T-cell therapy. Cancers (Basel) 13, 4279 (2021).","journal-title":"Cancers (Basel)"},{"key":"941_CR18","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel, J. Y. et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat. Med. 27, 1419\u20131431 (2021).","journal-title":"Nat. Med."},{"key":"941_CR19","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"941_CR20","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","volume":"403","author":"E Silkenstedt","year":"2024","unstructured":"Silkenstedt, E., Salles, G., Campo, E. & Dreyling, M. B-cell non-Hodgkin lymphomas. Lancet 403, 1791\u20131807 (2024).","journal-title":"Lancet"},{"key":"941_CR21","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1007\/s12325-023-02775-9","volume":"41","author":"A Ip","year":"2024","unstructured":"Ip, A. et al. Treatment outcomes with standard of care in relapsed\/refractory diffuse large B-cell lymphoma: real-world data analysis. Adv. Ther. 41, 1226\u20131244 (2024).","journal-title":"Adv. Ther."},{"key":"941_CR22","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1182\/blood-2023-173951","volume":"142","author":"M Hutchings","year":"2023","unstructured":"Hutchings, M. et al. Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume. Blood 142, 433 (2023).","journal-title":"Blood"},{"key":"941_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/bjh.19057","volume":"204","author":"A Dodero","year":"2024","unstructured":"Dodero, A. et al. Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas. Br. J. Haematol. 204, 151\u2013159 (2024).","journal-title":"Br. J. Haematol."},{"key":"941_CR24","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.3390\/cancers14102516","volume":"14","author":"V Rentsch","year":"2022","unstructured":"Rentsch, V. et al. Glofitamab treatment in relapsed or refractory DLBCL after CAR T-cell therapy. Cancers (Basel) 14, 2516 (2022).","journal-title":"Cancers (Basel)"},{"key":"941_CR25","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1097\/01.HS9.0000847704.12245.1f","volume":"6","author":"EC Piccione","year":"2022","unstructured":"Piccione, E. C. et al. P1210: immune correlates of response to glofitamab: biomarker findings from a pivotal phase II expansion study in patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL). Hemasphere 6, 1096\u20131097 (2022).","journal-title":"Hemasphere"},{"key":"941_CR26","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2023-179776","volume":"142","author":"S Nassiri","year":"2023","unstructured":"Nassiri, S. et al. Molecular mechanisms underlying response and resistance to glofitamab. Blood 142, 1619 (2023).","journal-title":"Blood"},{"key":"941_CR27","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont, C. et al. Epcoritamab, a novel, subcutaneous CD3\u00d7CD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J. Clin. Oncol. 41, 2238\u20132247 (2023).","journal-title":"J. Clin. Oncol."},{"key":"941_CR28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood.2021011994","volume":"141","author":"L Falchi","year":"2023","unstructured":"Falchi, L., Vardhana, S. A. & Salles, G. A. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood 141, 467\u2013480 (2023).","journal-title":"Blood"},{"key":"941_CR29","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz, K. F., Altman, D. G. & Moher, D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Brit. Med. J. 340, c332 (2010).","journal-title":"Brit. Med. J."},{"key":"941_CR30","doi-asserted-by":"publisher","first-page":"830773","DOI":"10.3389\/fimmu.2022.830773","volume":"13","author":"A Peinelt","year":"2022","unstructured":"Peinelt, A. et al. Monitoring of circulating CAR T cells: validation of a flow cytometric assay, cellular kinetics, and phenotype analysis following tisagenlecleucel. Front. Immunol. 13, 830773 (2022).","journal-title":"Front. Immunol."},{"key":"941_CR31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/cei.13491","volume":"202","author":"A Oras","year":"2020","unstructured":"Oras, A. et al. Comprehensive flow cytometric reference intervals of leukocyte subsets from six study centers across Europe. Clin. Exp. Immunol. 202, 363\u2013378 (2020).","journal-title":"Clin. Exp. Immunol."},{"key":"941_CR32","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"941_CR33","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130, 1800\u20131808 (2017).","journal-title":"Blood"},{"key":"941_CR34","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","volume":"48","author":"K Cocks","year":"2012","unstructured":"Cocks, K. et al. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur. J. Cancer 48, 1713\u20131721 (2012).","journal-title":"Eur. J. Cancer"},{"key":"941_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/147176","volume":"2013","author":"FJ Hlubocky","year":"2013","unstructured":"Hlubocky, F. J. et al. The development and validation of a measure of health-related quality of life for non-Hodgkin\u2019s lymphoma: the functional assessment of cancer therapy\u2014lymphoma (FACT-Lym). Lymphoma 2013, 147176 (2013).","journal-title":"Lymphoma"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00941-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00941-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00941-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T08:30:13Z","timestamp":1757147413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00941-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["941"],"URL":"https:\/\/doi.org\/10.1038\/s43018-025-00941-2","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.C. has received honoraria and advisory\/consultancy fees from Roche, Bristol-Myers Squibb, BeiGene, Novartis, Kite\/Gilead, Takeda, AstraZeneca, AbbVie, Janssen, Onward Therapeutics and Mabqi. R.H. has received honoraria from Kite\/Gilead, Novartis, Incyte, Janssen, MSD, Takeda and Roche and is a member on the board of directors or advisory committee of Kite\/Gilead, Novartis, Bristol-Myers Squibb\/Celgene, ADC Therapeutics, Incyte and Miltenyi. L.Y. has received honoraria and advisory\/consultancy fees from AbbVie, AstraZeneca, BeiGene, Bristol-Myers Squibb\/Celgene, Gilead\/Kite, Janssen and Roche. S.C. has received honoraria and advisory\/consultancy fees from AbbVie, AstraZeneca, Atara, BeiGene, Gilead\/Kite, Janssen, Novartis, Pierre Fabre and Takeda. F.J. has received honoraria and advisory\/consultancy fees from Roche, Bristol-Myers Squibb, Novartis, Kite\/Gilead, Takeda, AbbVie and Janssen. F-X.G. has received honoraria and advisory\/consultancy fees from Bristol-Myers Squibb, Novartis, Kite\/Gilead, AstraZeneca, Janssen and Miltenyi. F.M. has received consultancy fees from AbbVie, Bristol-Myers Squibb, Gilead, Novartis and Roche, serves as an advisor for AbbVie, Gilead and Roche and has received honoraria from Chugai and Kaleda for scientific lectures. O.C. has received honoraria and advisory\/consultancy fees from Roche, Takeda, Gilead\/Kite, Bristol-Myers Squib, MSD, AbbVie, BeiGene and ADC therapeutics. T.G. has received travel and accommodation expenses from Roche. C.T. has received honoraria and advisory\/consultancy fees from Roche, Bristol-Myers Squibb, Novartis, Kite\/Gilead, Takeda, AbbVie and Janssen. L.D.L.R. has received honoraria and advisory\/consultancy fees from Gilead\/Kite, Novartis, Bristol-Myers Squibb, Janssen and Takeda. P.F. has received honoraria and advisory\/consultancy fees from BeiGene, Kite\/Gilead, AstraZeneca, AbbVie and Janssen. S.G. is an employee of LYSARC. P.S. has received honoraria and advisory\/consultancy fees from Janssen, Roche, Bristol-Myers Squibb, AbbVie, AstraZeneca, Chugai, Novartis and Kite\/Gilead. Y.A.T., M.J., C.L., F.L.B., A.M., J-O.B., C.R., L.R. and K.T. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}